CHMP

Committee for Medicinal Products for Human Use.

The Committee for Medicinal Products for Human Use (CHMP) is a scientific committee of the European Medicines Agency (EMA) responsible for evaluating the safety, efficacy, and quality of medicinal products for human use. The CHMP is made up of experts in a wide range of scientific and medical disciplines, including pharmacology, toxicology, and clinical medicine. The primary role of the CHMP is to provide scientific advice to the EMA on the authorization of medicinal products for human use in the European Union (EU). The committee assesses applications for marketing authorization, as well as applications for changes to existing marketing authorizations, such as new indications or dosages. The CHMP also reviews data on the safety and efficacy of medicinal products and makes recommendations to the EMA on the use of these products in clinical practice.

The CHMP works closely with national regulatory authorities in the EU to ensure that medicinal products authorized for use in the EU meet the highest standards of safety, efficacy, and quality. The committee also works to ensure that patients have access to new and innovative treatments in a timely manner while balancing the risks and benefits of these treatments.